You are here: Industry Insights > Shire

News List

FDA grants orphan drug status to Shire’s UC treatment SHP647 pharmaceutical-technology
December 04, 2017
FDA has granted orphan drug designation to Shire’s investigational mucosal addressin cell adhesion molecule-1 antibody, SHP647, for the treatment of paediatric patients with moderately to severely active ulcerative colitis
Shire to streamline operations with 100-strong plant sale and in-house Cinryze production pharmafile
November 01, 2017
Shire has revealed that it plans to sell one of its manufacturing sites in Milford, Massachusetts, having already entered active negotiations with prospective buyers.
Shire’s haemophilia A gene therapy wins Orphan status pharmatimes
October 27, 2017
Shire’s gene therapy candidate SHP654, an investigational factor VIII gene therapy for the treatment of haemophilia A, has been awarded Orphan Dr
Shire’s lyophilised Oncaspar receives positive CHMP opinion for ALL in Europe pharmaceufical-technology
October 17, 2017
The CHMP's positive opinion recommends the marketing authorisation of lyophilised Oncaspar as a component of antineoplastic combination therapy in ALL in paediatric patients from birth to 18 years and in adult patients.
Shire’s Intuniv hits targets in adult ADHD trial pharmatimes
September 21, 2017
Data from a Phase III study evaluating Shire’s Intuniv in Japan in adults with attention deficit hyperactivity disorder indicate that the drug could improve symptoms of the condition in this patient group.
Shire disputes employee dissatisfaction report as UBS slashes price target fiercepharma
August 31, 2017
Shire last year bought Baxalta for $32 billion.
Shire launches new ADHD drug Mydayis as it weighs a neuroscience exit fiercepharma
August 29, 2017
Shire announced a copay offer with its full U.S. launch of Mydayis, a reformulation of its well-known Adderall.
Chutes & Ladders—Shire CFO’s abrupt exit worries investors fiercebiotech
August 25, 2017
CFO Jeff Poulton's plan to leave Shire at the end of the year stirred up uneasiness among investors.
Shire CFO, along with analysts, tries to placate investors after surprise exit news sent shares sout fiercepharma
August 23, 2017
Shire's CFO will depart by the end of the year.
Shire Director and Senior Management Changes americanpharmaceuticalreview
August 22, 2017
Shire has announced changes to its Executive Committee.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page